Trial Profile
A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Firuglipel (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 27 Feb 2018 Results published in the Advances in Therapy
- 15 Sep 2017 Primary endpoint has been met. (change in HbA1c compared with placebo) as per results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes